Pfizer Q3 revenue $17.2B as COVID annualization drags reported growth negative
The COVID distortion is in its last year and oncology is being reported through
The ex-COVID base is now the correct modeling denominator, and inside it the oncology franchise carries the growth. The perioperative label matters more than its size suggests because it moves the product into the curative setting, where duration caps revenue per patient but the addressable population is defined by diagnosis rather than by metastatic progression.
Pfizer reported third-quarter revenue of $17.2 billion, down 3 percent year over year, as sales of its COVID-19 vaccine and antiviral continued to annualize from pandemic-era peaks. Excluding COVID products, revenue grew 8 percent operationally, led by oncology, where revenue rose 16 percent, and by the migraine and anti-infective franchises. The company maintained full-year guidance of $61 to $64 billion in revenue and adjusted earnings of $3.05 to $3.25 per share. CFO Dave Denton said the company retired roughly $3.5 billion of COVID product inventory during the quarter and does not expect further write-downs. CEO Albert Bourla said the company's revenue base excluding COVID products has compounded at 9 percent over two years. Net debt fell $2.4 billion sequentially to $57 billion.
The reported decline is entirely a COVID comparison effect. Ex-COVID growth of 8 percent with oncology at 16 percent is the number the company wants the model to use, and guidance held through the transition.
The COVID decline is finally becoming an accounting fact instead of a narrative. The nine percent ex-COVID compound is a two-year window chosen by someone who knows which window flatters.
- Revenue of $17.2 billion, down 3 percent as COVID product sales annualize
- Ex-COVID revenue grew 8 percent operationally with oncology up 16 percent
- Full-year guidance maintained at $61 to $64 billion and $3.05 to $3.25 adjusted EPS
- Roughly $3.5 billion of COVID inventory retired with no further write-downs expected